Key Takeaways
- • NEA (New Enterprise Associates) filed Amendment No. 4 to its Schedule 13D for Monte Rosa Therapeutics (NASDAQ: GLUE), updating its ownership disclosure following recent corporate actions including share distributions and sales.
- • The amendment updates NEA's previously reported stake, with the filing indicating changes to the venture capital firm's position in the biotechnology company following adjustments to Monte Rosa's outstanding share count.
- • Monte Rosa Therapeutics maintains a robust cash position of $671 million in cash and equivalents, providing runway for its molecular glue degrader platform development.
- • The company has secured strategic partnerships including a global license agreement with Novartis (providing $120 million upfront plus milestone payments) and a collaboration with Roche focused on discovering molecular glue degraders.
- • NEA's control structure through NEA 17 L.P., NEA Partners 17 L.P., and NEA 17 GP LLC is managed by Executive Committee members including Anthony Florence, Jr., Mohamad Makhzoumi, and Scott Sandell.
Summary
New Enterprise Associates filed Amendment No. 4 to its Schedule 13D filing for Monte Rosa Therapeutics, Inc. on July 6, 2026, reflecting adjustments to its ownership stake in the biotechnology company following share distributions and sales. The amendment updates the initial Schedule 13D filed July 12, 2021, and supersedes three prior amendments filed in May 2024, August 2024, and March 2026. The filing addresses changes resulting from corporate actions that affected both NEA's share count and Monte Rosa's outstanding share base.
Monte Rosa Therapeutics operates as a clinical-stage biotechnology company developing a molecular glue platform designed to degrade disease-causing proteins. The company's financial position remains solid with $671 million in cash and equivalents on its balance sheet. The firm has established meaningful partnerships to advance its pipeline, including a global license agreement with Novartis that provided $120 million in upfront payments plus additional option payments and potential milestone-based compensation. Separately, Monte Rosa entered a strategic collaboration with Roche to discover molecular glue degraders targeting specific disease pathways.
NEA's stake in Monte Rosa is managed through a control structure involving NEA 17, L.P. as the primary investment vehicle, with NEA Partners 17, L.P. serving as its sole general partner and NEA 17 GP, LLC as the sole general partner of NEA Partners 17. The Executive Committee overseeing the investment includes Anthony A. Florence, Jr., Mohamad H. Makhzoumi, and Scott D. Sandell, alongside board observers Forest Baskett, Ali Behbahani, Carmen Chang, Edward T. Mathers, Paul Walker, and Rick Yang. The filing's Amendment No. 4 maintains consistency with previously reported information except where specific updates to ownership percentages and share counts reflect the changes disclosed herein.
Monte Rosa Therapeutics operates as a clinical-stage biotechnology company developing a molecular glue platform designed to degrade disease-causing proteins. The company's financial position remains solid with $671 million in cash and equivalents on its balance sheet. The firm has established meaningful partnerships to advance its pipeline, including a global license agreement with Novartis that provided $120 million in upfront payments plus additional option payments and potential milestone-based compensation. Separately, Monte Rosa entered a strategic collaboration with Roche to discover molecular glue degraders targeting specific disease pathways.
NEA's stake in Monte Rosa is managed through a control structure involving NEA 17, L.P. as the primary investment vehicle, with NEA Partners 17, L.P. serving as its sole general partner and NEA 17 GP, LLC as the sole general partner of NEA Partners 17. The Executive Committee overseeing the investment includes Anthony A. Florence, Jr., Mohamad H. Makhzoumi, and Scott D. Sandell, alongside board observers Forest Baskett, Ali Behbahani, Carmen Chang, Edward T. Mathers, Paul Walker, and Rick Yang. The filing's Amendment No. 4 maintains consistency with previously reported information except where specific updates to ownership percentages and share counts reflect the changes disclosed herein.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.